The Evaluation Operating System

In high-stakes clinical environments, the gap between a generator and a verifier is often non-existent—if a verifier were good enough to trust, it would already be the generator. To solve this, Abridge treats evaluation as the company's primary operating system rather than an afterthought.

Instead of relying on a single "correct" answer, they use a rigorous, multi-layered rubric system:

  • Rubric Creation: Two independent physicians draft elements of a high-quality response. A third physician adjudicates these into a single master rubric, and a fourth performs quality assurance.
  • Multi-Dimensional Judges: Rather than one judge, the system employs separate, expert-calibrated LLM judges for clinical quality, safety, adversarial boundaries, and tone.
  • Feedback Loops: By encoding clinician judgment into these judges, non-clinician engineers can iterate and "hill climb" on product performance with confidence that the system reflects actual medical standards.

Optimizing for Scale and Cost

Processing 100 million medical conversations annually requires balancing frontier-level intelligence with strict latency and cost constraints. Abridge avoids the "frontier model for everything" trap by decomposing complex tasks into granular workflows.

  • Model Decomposition: Instead of using a single large model for an entire clinical note, the team post-trains smaller, specialized models for specific sections (e.g., History of Present Illness vs. Assessment and Plan). This reduces latency and compute costs while maintaining high quality.
  • Event-Driven Triggering: To handle tasks like in-visit order entry, the system uses a tiered architecture. Lightweight, fast models monitor the conversation for specific triggers; only when a relevant event is detected does the system hand off to larger, more expensive models to perform the heavy lifting of order matching and validation.
  • The Data Flywheel: Abridge bets that their proprietary, large-scale dataset of clinical conversations provides a "right to win" that generic frontier models cannot match. By focusing on narrow, high-value clinical problems, they aim to outpace the rate of improvement of general-purpose models.